New Hope for Lung Cancer Patients | Tedopi Vaccine Reduces Death Risk by Nearly Half

A French biotechnology company has reported a promising cancer vaccine that effectively reduces the risk of death from lung cancer. Ose Immunotherapeutics announced that its Tedopi vaccine demonstrated a 41% decrease in mortality risk for certain lung cancer patients.

The vaccine, Tedopi, has exhibited its potential to decrease mortality rates in certain lung cancer patients. Lung cancer ranks as the leading cause of cancer-related deaths in Europe and the United States.

The outcomes of a phase 3 clinical trial show the therapeutic benefits of this vaccine. This was published in the Annals of Oncology journal.

This study focused on patients with advanced non-small cell lung cancer (NSCLC), primarily adenocarcinoma, the most prevalent form of lung cancer. Adenocarcinoma is often less responsive to chemotherapy and radiation therapy, as the US Cancer Institute noted.

In the study, 219 patients, all of whom had resisted other treatments, participated across nine European countries and the United States. Of these, 139 patients received the Tedopi vaccine. And the other 80 received chemotherapy.

Patients receiving Tedopi displayed notably higher survival rates and improved quality of life than those undergoing chemotherapy.

“A significant 41% reduction in the risk of death was observed, associated with an improved tolerance score and maintained quality of life.”

Professor Benjamin Besse, the study’s lead author from the Gustave Roussy Institute

Phase 3 trials

In this trial, Ose Immunotherapeutics’ vaccine was used as a third-line treatment. And it indicates that patients had previously undergone two other therapies. Besse suggested that further evaluation in second-line treatment for advanced and metastatic NSCLC should be explored, potentially extending the availability of this cancer vaccine to patients with limited treatment options and significant medical needs.

The Tedopi vaccine has shown effectiveness in patients possessing the HLA-A2 gene. HLA-A2 gene is present in approximately half of the population. The administration schedule involves an initial dose every three weeks. And followed by maintenance doses every eight weeks for one year and subsequently every 12 weeks.

Nicolas Poirier, CEO of Ose Immunotherapeutics, expressed enthusiasm for the recent trial results. He highlighted the potential of this novel class of therapeutic vaccines.

Tedopi falls within the category of therapeutic cancer vaccines, designed to instruct the immune system to recognize and target tumor cells specifically. Essentially, these vaccines harness the patient’s own immune defenses to combat cancer.

Immunotherapy has made significant strides since the 2010s, with notable advancements spurred by research during the pandemic. Several immunotherapeutic treatments have gained approval, and ongoing research continues to expand possibilities in the field.

Earlier this year, the UK government initiated cancer vaccine trials through an agreement with BioNTech, with plans to treat up to 10,000 patients by 2030.

Despite the costly nature of these treatments, Market Future Insight projects that the global cancer vaccines market will reach a value of €22 billion by 2033.

Following the trial results announcement, Ose Immunotherapeutics’ stock saw a 60% increase in value on the Paris Stock Exchange.

Also read:

Similar Posts